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Abstract
Background: The coexistence of distinct neurodegenerative diseases in single cases has recently attracted greater
attention. The phenotypic co-occurrence of progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis
(ALS) has been documented in several cases. That said, the clinicopathological comorbidity of these two diseases
has not been demonstrated.
Case presentation: A 77-year-old man presented with gait disturbance for 2 years, consistent with PSP with progressive
gait freezing. At 79 years old, he developed muscle weakness compatible with ALS. The disease duration was 5 years after
the onset of PSP and 5months after the onset of ALS. Neuropathological findings demonstrated the coexistence of PSP
and ALS. Immunohistochemical examination confirmed 4-repeat tauopathy, including globose-type neurofibrillary
tangles, tufted astrocytes, and oligodendroglial coiled bodies as well as TAR DNA-binding protein 43 kDa pathology in
association with upper and lower motor neuron degeneration. Immunoblotting showed hyperphosphorylated full-length
4-repeat tau bands (64 and 68 kDa) and C-terminal fragments (33 kDa), supporting the diagnosis of PSP and excluding
other parkinsonian disorders, such as corticobasal degeneration. Genetic studies showed no abnormalities in
genes currently known to be related to ALS or PSP.
Conclusions: Our case demonstrates the clinicopathological comorbidity of PSP and ALS in a sporadic patient. The
possibility of multiple proteinopathies should be considered when distinct symptoms develop during the disease course.
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Background
Progressive supranuclear palsy (PSP) was originally de-
scribed as involving dystonic posturing of the neck and
axial rigidity, vertical supranuclear gaze palsy, postural
instability, gait disturbance with an ataxic quality, early
falls, dysarthria, dysphagia, and a poor levodopa response
[1]. PSP is neuropathologically characterized by extensive
degeneration of the globus pallidus, subthalamic nucleus,
substantia nigra, and pons as well as 4-repeat tau
accumulation in both neurons and glia [2, 3]. Broad
clinical phenotypes of PSP have been reported, including
Richardson’s syndrome, progressive gait freezing, corti-
cobasal syndrome, and primary lateral sclerosis (PLS) [4].
The PSP-PLS phenotype presents with upper motor
neuron involvement and isolated tau pathology without
TAR DNA-binding protein 43 kDa (TDP-43) pathology
[5, 6]. In contrast, amyotrophic lateral sclerosis (ALS) is
not regarded as a phenotype of PSP.
The co-occurrence of PSP and ALS has recently
attracted greater attention. The phenotypic coexistence
of PSP and ALS has been documented in several cases
[7–9]. Cases of ALS plus PSP-like syndrome due only to
TDP-43 proteinopathy have also been reported [10].
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These reports, however, fell short of demonstrating
neuropathology to begin with or dual neuropathologies.
Some PSP cases have accompanying TDP-43 pathology
in the limbic system and PSP-vulnerable regions, such as
the subthalamic nucleus, substantia nigra, and pontine
tegmentum, but not in the motor neuron system [11].
Thus, the neuropathological co-occurrence of ALS and
PSP has not been demonstrated. Here, we report a
unique case in which the coexistence of PSP and ALS
was demonstrated both clinically and pathologically.
Case presentation
A 77-year-old man visited our hospital due to short-
stepped gait and falls, which started two years before.
He had a past history of herniated lumber disc, cataract,
and benign prostatic hyperplasia. His family history was
unremarkable. Neurological examination revealed brady-
kinesia, mildly reduced arm swing on the right when
walking, and retropulsion. He did not present eye
movement abnormalities, resting or postural tremors,
apparent rigidity, or signs of autonomic impairment.
Brain MRI revealed mild frontal lobe atrophy and mild
right-dominant subdural hygroma (Fig. 1a). Levodopa/
carbidopa hydrate was started but discontinued shortly
due to side effects.
Nine months later, he was referred to us again due to for-
getfulness and progressive gait disturbance. Neurological
examination demonstrated scores of 26 and 16 in the
Mini-Mental State Examination and Hasegawa Dementia
Scale-Revised respectively, normal ocular and tongue
movements and limb muscular strength, a positive snout
reflex, a normal jaw jerk, increased tendon reflexes in the
extremities, normal plantar response, short-stepped gait
(especially on turning), retropulsion, and subsequent freez-
ing of gait. Dysphagia, tremors, and rigidity were absent;
muscular atrophy, fasciculation, and Hoffmann sign were
not documented. A combination of amantadine, pramipe-
xole, and levodopa/carbidopa hydrate, which was resumed,
was partially effective for gait disturbance, but he still had
falls and reported difficulty in writing. His body weight
decreased from 64 kg to 42 kg in approximately one year.
A follow-up MRI showed increased subdural hygroma and
atrophy in the midbrain tegmentum (Fig. 1b).
Thirteen months after the second visit, when he
was 79 years old, left- and proximal-dominant arm
weakness was noted. A brain computed tomography
revealed subdural hematoma predominantly on the
left (Additional file 1). He was admitted to our hospital
and underwent a burr-hole evacuation for the hematoma.
Bilateral arm weakness and dysarthria progressed after the
surgery. Neurological re-examination showed hypophonic
dysarthria (which was not spastic), prominent muscle
weakness in the shoulder girdle and upper limbs (manual





Fig. 1 Imaging findings. a A brain MRI performed at 77 years old revealed mild frontal lobe atrophy and mild right-dominant subdural hygroma.
b A follow-up MRI performed at 79 years old showed increased subdural hygroma and atrophy in the midbrain tegmentum. c Cardiac 123I-meta-
iodobenzylguanidine scintigraphy showed decreased uptake in the delayed phase, suggesting mild sympathetic denervation. d Brain N-isopropyl-
p-[123I]iodoamphetamine scintigraphy showed hypoperfusion in the bilateral frontal, parietal, and occipital lobes but not the basal ganglia,
thalamus, and cerebellum
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flexor 5/5, wrist extensor 4−/2, and finger extensor 4/4−)
but not the lower limbs (5/5), mild rigidity in the limbs
(without spasticity), an increased jaw reflex, Hoffmann
sign on the right, and equivocal plantar response bi-
laterally. Tendon reflexes were decreased in the left upper
limb, mildly increased in the left lower limb, and other-
wise normal. He had no restricted eye movement, dys-
phagia, tongue atrophy, apparent fasciculation, nuchal
rigidity, or sensory disturbances. An electrophysiological
study demonstrated active and chronic denervation with
profound fasciculation potentials in the muscles of the
brainstem, cervical, thoracic, and lumbar regions, fulfilling
the definition of lower motor neuron dysfunction accord-
ing to the updated Awaji criteria [12]. An ultrasono-
graphic study revealed atrophy in the left cervical nerve
roots and the left ulnar nerve and fasciculation in the
upper and lower limbs. On respiratory function test
(which was a poor study), %VC was 13.2 and FEV1% was
152.3. An arterial blood gas demonstrated pH 7.458,
PaCO2 46.7mmHg, PaO2 82.9mmHg, HCO3 32.3mEq/L,
and SaO2 96.3%. Cardiac
123I-meta-iodobenzylguanidine
scintigraphy showed decreased uptake in the delayed
phase, suggesting mild sympathetic denervation. Brain N-
isopropyl-p-[123I]iodoamphetamine scintigraphy showed
hypoperfusion in the bilateral frontal, parietal, and occipi-
tal lobes but not the basal ganglia, thalamus, and cerebel-
lum. He was diagnosed with clinically probable ALS
according to the revised El Escorial and updated Awaji
criteria, and riluzole was introduced. The score of ALS
Functional Rating Scale-Revised was 27. CO2 retention
worsened quickly, and dysphagia became apparent, re-
quiring nasogastric tube nutrition. Due to the worsening
of CO2 narcosis with aspiration pneumonia, he died at age
80 years old, five months after the development of muscle
weakness.
We performed a genetic analysis that included whole-
exome sequencing, and the results demonstrated that
there was no pathological variation in genes currently
known to be associated with PSP or ALS, including
MAPT and GRN. No hexanucleotide repeat expansion
was detected in C9orf72. The number of CAG repeats in
the ATXN2 gene was 25/25 (normal).
Neuropathological findings
The brain weight was 1,240 g. Macroscopic examination
revealed selective atrophy of the anterior cervical nerve
roots as well as mild atrophy of the precentral gyrus
(Fig. 2a). In sections, depigmentation of the substantia
nigra and atrophy of the tegmentum of the midbrain,
internal globus pallidus and subthalamic nucleus were
observed (Fig. 2b-d).
Microscopically, there was moderate to severe neu-
ronal loss in the spinal anterior horn at all levels of the
spinal cord (Fig. 3a) that relatively spares the Onufro-
wicz nuclei and Clarke’s column. Bunina bodies were
abundant in anterior horn cells (Fig. 3b). Macrophages
had aggregated in the corticospinal tracts, while myelin





Fig. 2 Macroscopic findings. The precentral gyrus showed mild atrophy (a). Depigmentation of the substantia nigra and atrophy of the
tegmentum was observed in the midbrain (b). The internal segment of the globus pallidus (c) and the subthalamic nucleus (d) were atrophied.
Scale bars: 1 cm (a-d)
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and gliosis were observed in the hypoglossal nuclei. In
the amygdala and area CA1 of the hippocampus, moder-
ate to severe neuronal loss and gliosis were noted. Betz
cells were mildly reduced, and some neuronophagia was
observed in the precentral gyrus (Fig. 3c). On immuno-
histochemistry, we found that phosphorylated TDP-43-
immunopositive neuronal cytoplasmic inclusions (NCIs)
and glial cytoplasmic inclusions (GCIs) were predomi-
nantly located in the spinal anterior horn cells, brain-
stem motor nuclei (including the hypoglossal, facial, and
trigeminal nuclei), the precentral gyrus, and the limbic
systems (including the amygdala, hippocampus, subicu-
lum, and entorhinal cortex) (Fig. 3d).
Moreover, the substantia nigra showed marked neur-
onal loss with astrogliosis, melanophagia, and globose-
shaped neurofibrillary tangles (NFTs) (Fig. 3e). NFTs had
accumulated in the oculomotor nuclei, while neuronal
loss was not obvious. Mild neuronal loss and grumose
degeneration were observed in the dentate nuclei of
the cerebellum. Neuronal loss and gliosis with accu-
mulation of NFTs were observed in the subthalamic
nucleus and globus pallidus. In addition, adequate
amounts of NFTs and coiled bodies, immunopositive
for phosphorylated tau and 4-repeat tau, were ob-
served in PSP-vulnerable areas, including the inferior
olivary nucleus, substantia nigra, subthalamic nucleus,
and globus pallidus (Fig. 3f, g). These structures
showed less immunoreactivity for 3-repeat tau. Tufted
astrocytes were abundant in the substantia nigra, red
nucleus, midbrain tectum, subthalamic nucleus, puta-
men, caudate nuclei, and precentral gyrus (Fig. 3h).
NFT, coiled bodies, and tufted astrocytes were also
observed following Gallyas-Braak staining.
The phosphorylated TDP-43-positive structures and 4-
repeat tau-positive structures did not colocalize, as
investigated by double immunohistochemistry in the
substantia nigra or precentral gyrus. Together, these
findings demonstrate the neuropathological coexistence
of ALS and PSP. Only a small number of NFTs that were
immunopositive for both RD4 and RD3 were detected in
restricted regions, such as the transentorhinal cortex.
This pathological feature was consistent with Braak NFT
stage Ι [13] and Braak AT8 stage Ι [14]. No deposition of
amyloid, argyrophilic grain, or α-synuclein was detected.
Immunoblotting showed hyperphosphorylated full-
length 4-repeat tau bands (64 and 68 kDa) and C-ter-
minal fragments (33 kDa) in the frontal cortex (Fig. 4).
This banding pattern was consistent with that previously
reported in PSP [15, 16].
The methods used in the above analyses are provided
in Additional file 2.
Discussion and conclusions
Here, we demonstrate a distinct case in which PSP and
ALS coexisted clinically and pathologically. Clinically,
our case corresponds to possible PSP with progressive
gait freezing and probable ALS [4, 12, 17]; as in our case,
variant PSP syndromes other than Richardson’s often
lack vertical gaze palsy [4]. Pathological investigation
demonstrated neuronal loss and degeneration in the
regions typically affected by PSP and ALS. We also
show that 4 repeat-tau accumulation was present in
A B C D 
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Fig. 3 Microscopic findings. The cervical spinal cord showed severe neuronal loss of anterior horn cells (a) and Bunina bodies (b). Neuronophagia
was observed in the precentral gyrus (c). Phosphorylated TDP-43 neuronal cytoplasmic inclusions were present in the precental gyrus (d).
Globose-shaped neurofibrillary tangle (NFT) was detected in the substantia nigra by H-E staining (e) and immunostaining for phosphorylated tau
(f) and 4-repeat tau (g). Tufted astrocytes were present in the putamen (h). Scale bars: 500 μm (a), 20 μm (b-h)
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the PSP-associated regions, while TDP-43 accumulation
was present in the ALS-related regions [3, 18], supporting
the dual pathologies of PSP and ALS. Moreover, the
biochemical findings of tau also confirmed the diagnosis
of PSP and excluded corticobasal degeneration.
Given that both PSP (with Richardson’s syndrome;
3.1–13.8 per 100,000 persons [19–21]) and ALS (5.0–
10.3 per 100,000 persons [22–24]) are rare, the acciden-
tal comorbidity of PSP and ALS is highly unlikely.
Rather, our case may accord with the high frequency of
multiple pathologies in single cases, as revealed by
recent advances in immunohistochemical methods
[25, 26]. PSP sometimes accompanies other neurodege-
nerative pathologies, although they do not necessarily cor-
respond to clinical symptoms. For instance, a PSP brain is
apparently accompanied by TDP-43 pathology more often
than a normal aging brain [11, 26, 27]. Furthermore, there
have been reports of cases with both PSP and other
neurodegenerative pathologies, such as Alzheimer’s di-
sease [28, 29], Lewy body disease [30], and ballooned
neurons due to argyrophilic grain disease [31]. Cases of
PSP with multiple system atrophy [32, 33] and Pick bodies
[34] have also been reported.
Conversely, tau pathology can be observed in ALS or
frontotemporal lobar degeneration with TDP-43 path-
ology (FTLD-TDP). In one study, tau pathology of Braak
NFT stage III or higher, which is apparently related to
Alzheimer’s pathology, was observed in over 15% of ALS
and FTLD-TDP cases [26]. In addition, co-occurrence of
argyrophilic grain disease, in which phosphorylated 4-re-
peat tau is the pathological protein, was documented in
approximately 40% of ALS cases [35]. These findings in-
dicate that the coexistence of 3- or 4-repeat tauopathies
in ALS and FTLD-TDP is not uncommon. Of further
note, the comorbidity of PSP-tau and FTLD-TDP has
been reported in two cases. However, these cases lacked
ALS-associated symptoms, such as muscle weakness and
atrophy, or pathological changes in the motor neuron
system [36]. Accordingly, our case represents a unique
example of the clinical and pathological comorbidity of
PSP and ALS.
That being said, as PSP per se can involve mild neu-
ronal loss and NFTs in the spinal anterior horn, which
possibly present as clinical symptoms [37], one may
argue that the progressive weakness observed in our case
could also be attributed to PSP pathology alone. In our
case, however, neuronal loss and accumulation of TDP-
43 inclusions were obvious in the spinal anterior horn,
while NFTs and phosphorylated tau accumulation were
tau C
Fig. 4 Immunoblot analysis of sarkosyl-insoluble tau. Full-length
hyperphosphorylated tau bands indicated by 64, 68 kD and ~ 33 kDa
fragments were detected, consistent with a progressive supranuclear
palsy tau banding pattern
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scarce there. The distribution patterns of TDP-43 vs. tau
pathologies were also found in the hypoglossal and facial
nuclei, consistent with ALS pathology. Accordingly, the
progressive weakness was likely due to the concurrent
ALS pathology rather than phenotypic variation of PSP.
We note that there was little regional overlap between
the ALS and PSP pathologies. Even in some regions in
which both tau and TDP-43 pathologies were abundant
(e.g., the precentral gyrus and substantia nigra), the se-
verity of neuronal loss was similar to that observed in
typical cases of PSP or ALS. Furthermore, we found no
colocalization of 4-repeat tau and phosphorylated TDP-
43 on double immunohistochemistry. These findings do
not support the notion that mutual exacerbation of the
dual pathologies occurred in our case. That said, the co-
occurrence per se may have contributed to the short
duration of ALS observed in our case (5 months).
We are aware that the combination of ALS and
parkinsonism is a feature of the ALS-parkinsonism-de-
mentia complex in the Kii peninsula of Japan (Kii ALS/
PDC), in which the disease presents with NFTs of Alz-
heimer’s type without amyloid deposition, TDP-43 path-
ology, and α-synuclein pathology to varying degrees.
However, the Kii ALS/PDC lacks tufted astrocytes [38],
which we observed in our case. In addition, the Kii ALS/
PDC showed hyperphosphorylated tau triplet bands at
60, 64, and 68 kDa on immunoblotting [39, 40]. Our
case showed no 60 kDa band, in contrast with the Kii
ALS/PDC. Taken together, we suggest that the neuro-
pathological findings in our case are distinct from those
of the Kii ALS/PDC.
We note that genetic abnormalities can be associated
with PSP, ALS, and related disorders. For instance,
C9orf72 repeat expansions, which account for a large
proportion of ALS and FTLD cases, are a rare genetic
cause of parkinsonism, such as Parkinson’s disease, corti-
cobasal syndrome, and PSP [41]. Mutations in MAPT
and GRN have also been detected in PSP, CBS, and
FTLD [42], and TBK1 mutations can manifest as ALS,
FTLD, or PSP [43]. Furthermore, genetic abnormalities
in C9orf72 versus GRN are associated with the degree of
NFT tau pathology in FTLD, suggesting a role for
C9orf72 mutations in multiple proteinopathies [44].
However, in our case, the genetic studies, which in-
cluded whole-exome sequencing, excluded genetic ab-
normalities known to be associated with these disorders.
The findings reported in our case show that distinct
phenotypes, PSP and ALS, and their corresponding
pathologies, including tauopathy and TDP-43 proteino-
pathy, can occur in a single case. Clinical symptoms
distinct from those of the original syndromes, e.g.,
muscle atrophy and weakness in the course of atypical
parkinsonism, should alert clinicians to the possibility of
overlapping pathologies. It is crucial to recognize that
overlapping pathologies can occur in single cases as dis-
tinct therapies become available or are being developed
for distinct diseases, e.g., riluzole and edaravone for ALS
and anti-tau immunotherapies for PSP. Furthermore,
future clinical trials may have to consider the possibility
of multiple pathologies to appropriately assess the
efficacy of drug candidates.
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